These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

387 related items for PubMed ID: 19264882

  • 1. A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration.
    Rohrer B, Long Q, Coughlin B, Wilson RB, Huang Y, Qiao F, Tang PH, Kunchithapautham K, Gilkeson GS, Tomlinson S.
    Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3056-64. PubMed ID: 19264882
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Systemic human CR2-targeted complement alternative pathway inhibitor ameliorates mouse laser-induced choroidal neovascularization.
    Rohrer B, Coughlin B, Bandyopadhyay M, Holers VM.
    J Ocul Pharmacol Ther; 2012 Aug; 28(4):402-9. PubMed ID: 22309197
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Regulatable Complement Inhibition of the Alternative Pathway Mitigates Wet Age-Related Macular Degeneration Pathology in a Mouse Model.
    Parsons NB, Annamalai B, Rohrer B.
    Transl Vis Sci Technol; 2023 Jul 03; 12(7):17. PubMed ID: 37462980
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The use of Matrigel combined with encapsulated cell technology to deliver a complement inhibitor in a mouse model of choroidal neovascularization.
    Annamalai B, Parsons N, Brandon C, Rohrer B.
    Mol Vis; 2020 Jul 03; 26():370-377. PubMed ID: 32476817
    [Abstract] [Full Text] [Related]

  • 8. Preliminary in vitro and in vivo assessment of a new targeted inhibitor for choroidal neovascularization in age-related macular degeneration.
    Li W, Dong L, Ma M, Hu B, Lu Z, Liu X, Liu J, Li X.
    Drug Des Devel Ther; 2016 Jul 03; 10():3415-3423. PubMed ID: 27799741
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Delivery of CR2-fH Using AAV Vector Therapy as Treatment Strategy in the Mouse Model of Choroidal Neovascularization.
    Schnabolk G, Parsons N, Obert E, Annamalai B, Nasarre C, Tomlinson S, Lewin AS, Rohrer B.
    Mol Ther Methods Clin Dev; 2018 Jun 15; 9():1-11. PubMed ID: 29234687
    [Abstract] [Full Text] [Related]

  • 11. A Targeted Inhibitor of the Alternative Complement Pathway Accelerates Recovery From Smoke-Induced Ocular Injury.
    Woodell A, Jones BW, Williamson T, Schnabolk G, Tomlinson S, Atkinson C, Rohrer B.
    Invest Ophthalmol Vis Sci; 2016 Apr 15; 57(4):1728-37. PubMed ID: 27064393
    [Abstract] [Full Text] [Related]

  • 12. Mechanisms of FH Protection Against Neovascular AMD.
    Borras C, Delaunay K, Slaoui Y, Abache T, Jorieux S, Naud MC, Sanharawi ME, Gelize E, Lassiaz P, An N, Kowalczuk L, Ayassami C, Moulin A, Behar-Cohen F, Mascarelli F, Dinet V.
    Front Immunol; 2020 Apr 15; 11():443. PubMed ID: 32318056
    [Abstract] [Full Text] [Related]

  • 13. Local production of the alternative pathway component factor B is sufficient to promote laser-induced choroidal neovascularization.
    Schnabolk G, Coughlin B, Joseph K, Kunchithapautham K, Bandyopadhyay M, O'Quinn EC, Nowling T, Rohrer B.
    Invest Ophthalmol Vis Sci; 2015 Jan 15; 56(3):1850-63. PubMed ID: 25593023
    [Abstract] [Full Text] [Related]

  • 14. The alternative pathway is required, but not alone sufficient, for retinal pathology in mouse laser-induced choroidal neovascularization.
    Rohrer B, Coughlin B, Kunchithapautham K, Long Q, Tomlinson S, Takahashi K, Holers VM.
    Mol Immunol; 2011 Mar 15; 48(6-7):e1-8. PubMed ID: 21257205
    [Abstract] [Full Text] [Related]

  • 15. Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice.
    Banda NK, Levitt B, Glogowska MJ, Thurman JM, Takahashi K, Stahl GL, Tomlinson S, Arend WP, Holers VM.
    J Immunol; 2009 Nov 01; 183(9):5928-37. PubMed ID: 19828624
    [Abstract] [Full Text] [Related]

  • 16. Encapsulated Cell Technology-Based Delivery of a Complement Inhibitor Reduces Choroidal Neovascularization in a Mouse Model.
    Annamalai B, Parsons N, Belhaj M, Brandon C, Potts J, Rohrer B.
    Transl Vis Sci Technol; 2018 Mar 01; 7(2):3. PubMed ID: 29576927
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of the alternative complement pathway accelerates repair processes in the murine model of choroidal neovascularization.
    Parsons N, Annamalai B, Obert E, Schnabolk G, Tomlinson S, Rohrer B.
    Mol Immunol; 2019 Apr 01; 108():8-12. PubMed ID: 30763805
    [Abstract] [Full Text] [Related]

  • 18. New Insights on Complement Inhibitor CD59 in Mouse Laser-Induced Choroidal Neovascularization: Mislocalization After Injury and Targeted Delivery for Protein Replacement.
    Schnabolk G, Beon MK, Tomlinson S, Rohrer B.
    J Ocul Pharmacol Ther; 2017 Jun 01; 33(5):400-411. PubMed ID: 28333572
    [Abstract] [Full Text] [Related]

  • 19. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice.
    Sekine H, Kinser TT, Qiao F, Martinez E, Paulling E, Ruiz P, Gilkeson GS, Tomlinson S.
    Arthritis Rheum; 2011 Apr 01; 63(4):1076-85. PubMed ID: 21452327
    [Abstract] [Full Text] [Related]

  • 20. Excessive retinol intake exacerbates choroidal neovascularization through upregulated vascular endothelial growth factor in retinal pigment epithelium in mice.
    Tan X, Takahashi H, Nishida J, Aoki A, Inoue T, Yanagi Y.
    Exp Eye Res; 2015 Feb 01; 131():77-83. PubMed ID: 25576666
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.